Latest Information

Votrient (pazopanib) Approved by Health Canada for the Treatment of Renal Cell Carcinoma

Wednesday, June 16, 2010
Health Canada has approved Votrient (pazopanib) for metastatic renal cell carcinoma.

Friday, June 4, 2010
Effective June 14, 2010 Torisel will be funded in Ontario under the Ministry of Health

Macrocytosis with sunitinib: Canadian data

Wednesday, May 26, 2010
A Canadian retrospective single-centre review of advanced RCC patients reports that macrocytosis occurred in 21 of 43 patients (48.8%) during sunitinib treatment.

Torisel Approved in Ontario

Thursday, July 08, 2010 - 14:27 - admin

Friday, June 4, 2010
Original Article

Effective June 14, 2010 Torisel will be funded in Ontario under the Ministry of Health and Long Term Care / Cancer Care Ontario's new Drug Funding Program as a first-line treatment for mrcc patients with poor prognosis (including non-clear cell histology).

Filed Under: Uncategorized